title: Two-year safety and effectiveness of the platinum chromium everolimus-eluting stent for the treatment of small vessels and longer lesions.
abstract: OBJECTIVE
  To report 1- and 2-year clinical outcomes of patients receiving platinum chromium everolimus-eluting stents (PtCr-EES) in the prospective, single-arm PLATINUM small vessel (SV) and long lesion (LL) studies.
  
  
  BACKGROUND
  Small vessel diameter and long lesion length are independently associated with increased risk of adverse cardiac events after drug-eluting stent implantation.
  
  
  METHODS
  The PLATINUM SV study enrolled 94 patients with coronary artery lesions in vessels ≥2.25 mm to <2.50 mm in diameter and ≤28 mm in length. The PLATINUM LL study enrolled 102 patients with lesions >24 to ≤34 mm long in vessels ≥2.50 to ≤4.25 mm in diameter. The primary endpoint for both studies was target lesion failure (TLF) at 1 year compared to a prespecified performance goal based on outcomes with the TAXUS Express paclitaxel-eluting stent in small vessels and long lesions.
  
  
  RESULTS
  One-year TLF rates with the PtCr-EES were significantly (P < 0.001) lower than the predetermined performance goals: 2.4% versus 21.1% in the SV cohort and 3.2% versus 19.4% in the LL cohort. Cumulative rates of TLF to 2 years were 4.7% in the SV cohort and 8.8% in the LL cohort. No myocardial infarction or ARC definite/probable stent thromboses occurred in either cohort through 2-year follow-up.
  
  
  CONCLUSIONS
  The clinical efficacy and safety outcomes observed in these small vessel and long lesion cohorts support the use of the PtCr-EES in the treatment of small diameter vessels and long lesions.
authors.affiliation: Scripps Clinic, Division of Cardiovascular Diseases, La Jolla, California.
authors.forename: Paul S
authors.initials: PS
authors.lastname: Teirstein
authors.forename: Ian T
authors.initials: IT
authors.lastname: Meredith
authors.forename: Robert L
authors.initials: RL
authors.lastname: Feldman
authors.forename: A Charles
authors.initials: AC
authors.lastname: Rabinowitz
authors.forename: Louis A
authors.initials: LA
authors.lastname: Cannon
authors.forename: Tommy C
authors.initials: TC
authors.lastname: Lee
authors.forename: Joseph
authors.initials: J
authors.lastname: Dens
authors.forename: Christophe L
authors.initials: CL
authors.lastname: Dubois
authors.forename: Michael R
authors.initials: MR
authors.lastname: Mooney
authors.forename: Vincent J
authors.initials: VJ
authors.lastname: Pompili
authors.forename: Shigeru
authors.initials: S
authors.lastname: Saito
authors.forename: Dominic J
authors.initials: DJ
authors.lastname: Allocco
authors.forename: Keith D
authors.initials: KD
authors.lastname: Dawkins
authors.forename: Gregg W
authors.initials: GW
authors.lastname: Stone
mesh_terms: D000368:Aged; D002317:Cardiovascular Agents / Q000008:administration & dosage*; D002857:Chromium; D003324:Coronary Artery Disease / Q000175:diagnosis / Q000628:therapy*; D054855:Drug-Eluting Stents; D005060:Europe; D000068338:Everolimus; D005260:Female; D006801:Humans; D007564:Japan; D008297:Male; D008875:Middle Aged; D009520:New Zealand; D062645:Percutaneous Coronary Intervention / Q000009:adverse effects / Q000295:instrumentation*; D010984:Platinum; D011446:Prospective Studies; D011474:Prosthesis Design; D020123:Sirolimus / Q000008:administration & dosage / Q000031:analogs & derivatives*; D013997:Time Factors; D016896:Treatment Outcome; D014481:United States
chemical_list: D002317:Cardiovascular Agents; D002857:Chromium; D010984:Platinum; D000068338:Everolimus; D020123:Sirolimus
keywords: coronary stenosis; drug-eluting; everolimus; randomized controlled trial; stents